DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis

Company Overview

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company’s research is centered on therapies intended to address neurological and kidney-related conditions.

DiaMedica’s lead product candidate is rinvecalin, also known as DM199, a recombinant form of human tissue kallikrein-1. The company is evaluating rinvecalin as a potential treatment for acute ischemic stroke and kidney diseases, including conditions involving impaired renal function. The therapy is designed to activate the kallikrein-kinin system, which may help support blood flow and protect tissue.

DiaMedica is headquartered in Minneapolis, Minnesota, and conducts its development activities through clinical research programs and collaborations with medical institutions and research organizations. Rick Pauls serves as the company’s president and chief executive officer. As a clinical-stage biotechnology company, DiaMedica has not yet established a broad commercial product portfolio.

Key Stats

• Today's Range: $7.43 to $7.89
• 50-Day Range: $6.32 to $7.83
• 52-Week Range: $5.24 to $10.42
• Volume: 209,198 shs
• Average Volume: 162,047 shs
• Market Capitalization: $422.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

DiaMedica Therapeutics Stock Analysis - MarketRank™

DiaMedica Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 666th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DiaMedica Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

DiaMedica Therapeutics has a consensus price target of $12.00, representing about 53.3% upside from its current price of $7.83.

Amount of Analyst Coverage

DiaMedica Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for DiaMedica Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DiaMedica Therapeutics is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DiaMedica Therapeutics is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DiaMedica Therapeutics has a P/B Ratio of 7.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.71% of the float of DiaMedica Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

DiaMedica Therapeutics has a short interest ratio ("days to cover") of 36.67, which indicates bearish sentiment.

Change versus previous month

Short interest in DiaMedica Therapeutics has recently increased by 1.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DiaMedica Therapeutics does not currently pay a dividend.

Dividend Growth

DiaMedica Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.67

News Sentiment

DiaMedica Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for DiaMedica Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for DMAC on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.00% of the stock of DiaMedica Therapeutics is held by insiders.

Percentage Held by Institutions

10.12% of the stock of DiaMedica Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DMAC
• CIK: 1401040
• Web: www.diamedica.com
• Phone: (763) 496-5454
• Fax: N/A
• Employees: 35
• Year Founded: 2000

Price Target and Rating

• Average Price Target for DiaMedica Therapeutics: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +53.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.76%
• Return on Assets: -69.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.72
• Quick Ratio: 6.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.08 per share
• Price / Book: 7.25

Miscellaneous

• Outstanding Shares: 53,930,000
• Free Float: 51,230,000
• Market Cap: $422.27 million
• Optionable: Optionable
• Beta: 0.98